| *Together with | | NASDAQ: NLSP | Good day, 360 – | Here are our top investing ideas today – these setups look primed! Be the best prepared trader on the Street! | | | FULC - Up over 40% after FDA lifts clinical hold on Fulcrum Therapeutics' FTX-6058 for Sickle Cell Disease | FN - Up over 19% after earnings beat and positive guidance | ZM - Up over 4% after crushing earnings and increased guidance | | | *A message on behalf of Sica Media | Our Hot Stock Idea 🔥 today is: NLS Pharmaceutics AG (NASDAQ: NLSP). | NLSP is dedicated to helping patients worldwide access safer, better-tolerated and efficacious central nervous system (CNS) therapies. | The proprietary drugs they're releasing are poised to dominate a critical research field that's projected to account for over $6.6 billion by 2030… | Which is why we've already seen analysts projecting price points as high as $4, $5 and $6 — | That might not sound like a lot, but get this… yesterday this stock closed at a bargain 82 cents. | | That means the upside targets analysts are slapping on this stock are incredible compared to where things are today… | Jeff Bishop is super-excited about the "Gamma Trigger" setup he sees forming on NLSP right now. It is the same pattern he told all of his Bullseye Trades members about on QQQ yesterday – which helped him bag a huge overnight winner! | | As always, if you decide to trade this, do your due diligence, and start with the company's website here and see if NLSP has a place in your portfolio! | *Sponsored by Sica Media. Please see disclosures below. |
|
| | | FULC - Up over 40% after FDA lifts clinical hold on Fulcrum Therapeutics' FTX-6058 for Sickle Cell Disease | Fulcrum Therapeutics Inc (FULC) is a clinical-stage biopharmaceutical company, focusing on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. | This morning, the company announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for FTX-6058 for the potential treatment of sickle-cell disease (SCD). | Alex C. Sapir, Fulcrum's President and Chief Executive Officer, stated: | "Based on the initial data from the Phase 1b trial, which showed increasing levels of HbF with each dose escalation, we believe in the potential of FTX-6058 to not only shift the current standard of care but importantly, offer these patients a differentiated oral option. We look forward to building on these results with plans to resume enrollment for patients with SCD." | The stock is trading over 40% higher on the news. In addition, Stifel upgraded Fulcrum Therapeutics (FULC) to Buy, and announced an $11 price target for the stock. | | $5.66 has acted as resistance in the pre-market and will be an important level to watch today. | Above it the first major target for bulls is the pre-market high at $6.49. Beyond that, $7.50 and $9 come into play with a large gap to fill at $12.89. | Below $5.66, there is potential support at $5.40, $5, $4.40 and then a gap to fill at $3.92. | | FN - Up over 19% after earnings beat and positive guidance | Fabrinet (FN) provides optical packaging and precision optical, electro-mechanical and electronic manufacturing services in North America and internationally. The company offers a range of advanced optical and electro-mechanical capabilities in the manufacturing process, including process design and engineering, supply chain management, manufacturing, printed circuit board assembly, advanced packaging, integration, final assembly and testing. | After the close yesterday, FN reporting earnings of Q4 EPS of $1.86 vs $1.80 expected. Q4 revenue came in at $655.9 million vs $641.43 million expected. FN guided Q1 non-Gaap EPS of $1.83-$1.90. | The stock traded over 19% higher in pre-market after the earnings release. | | $138 was resistance in the after-hours and now becomes a potential area of support. | Above it the first major target is the pre-market high at $142.20. Beyond that, there is blue sky as the stock is trading at all-time highs. Round numbers such as $145 and $150 are potential targets. | Below $138, there is potential support at $136, $134, $132 and $129.60. | | ZM - Up over 4% after crushing earnings and increased guidance | Zoom Video Communications Inc (ZM) provides unified communications platforms in the Americas and internationally. The company offers Zoom meetings with HD video, voice, chat and content sharing through mobile devices, desktops, laptops, telephones and conference room systems. | ZM reported earnings after the close yesterday of Q2 EPS of $1.34 vs $1.06 expected. Revenue for the quarter was $1.14 billion vs $1.11 billion expected. | ZM guided Q3 2024 EPS of $1.07-$1.09 vs $1.03. Zoom sees Q3 2024 revenue of $1.115-1.12 billion, vs $1.13 billion expected. ZM sees FY2024 EPS of $4.63-$4.67 vs the consensus of $4.30. ZM sees FY2024 revenue of $4.485-4.495 billion vs $4.48 billion expected. | The stock is trading up over 4% in pre-market after the earnings release. | | $70 has acted as resistance so far in the after-hours and pre-market and will be an important level to watch. | Above it, targets to the upside are $71, $73 and then the after-hours high of $74.50. Beyond that $76, $78 and $80 come into play. | Below $70 there is potential support at $69, $68 with a gap to fill at $67.27. $66 and $64.50 are potential targets below that. | | | | Economic Calendar | | | To Your Success! | | *This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. | | | Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull | | | *PAID ADVERTISEMENT. Raging Bull has been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NLS Pharmaceutics AG from a period beginning on August 22 through August 24, 2023. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of NLS Pharmaceutics AG, increased trading volume, and possibly an increased share price of NLS Pharmaceutics AG's securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in NLS Pharmaceutics AG, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication. | FOR COMMERCIAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for commercial and informational purposes only. A portion of our business is engaged in the promotion, marketing, and advertising of companies including public companies. A portion of Raging Bull's business model is to receive financial compensation to promote public companies, conduct investor relations advertising and marketing, and publicly disseminate information regarding public companies through our websites email, SMS, and push notifications among other methods of communication. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. All material information contained in this advertisement is based on information generally available to the public, including information released to the public or filed by the Company with applicable regulators which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company's financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. | SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Never invest in any stock featured in this advertisement, on our site or emails unless you can afford to lose your entire investment. | NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. | USE OF FORWARD-LOOKING STATEMENTS. Our advertisements including this advertisement and related emails, reports and alerts may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information in this advertisement, related emails, reports or alerts or on our website or media webpage. This information is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as "believes," "anticipates," "estimates," "expects," "projects," "intends," or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www .sec .gov/edgar/searchedgar/companysearch |
|
| TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. |
|
| WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
| |
|
Post a Comment
Post a Comment